SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.

J Exp Clin Cancer Res · 2022 · PMC8793262 · PMID 35086552

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

4 h), being its expression in mesenchymal-like GBM also higher than in proneural-like GBM but this latter difference did not reach statistical significance (Fig. 4 h).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.